Halozyme

Halozyme Announces Positive CHMP Opinion for Bristol Myers Squibb’s Subcutaneous Opdivo® with ENHANZE

Halozyme Announces Positive CHMP Opinion for Bristol Myers Squibb’s Subcutaneous Opdivo® with ENHANZE Halozyme Therapeutics, Inc. (NASDAQ: HALO) recently announced a significant milestone in oncology treatment development, as Bristol Myers…

Read MoreHalozyme Announces Positive CHMP Opinion for Bristol Myers Squibb’s Subcutaneous Opdivo® with ENHANZE